OncoZenge AB (ONCOZ) AI Stock Analysis

OncoZenge AB

(Nasdaq OMX AB:ONCOZ)

Select Model

Rating:38Underperform

Price Target:SEK 3.00▼(-3.38% Downside)

Action:reiterated

Date:10/16/26

The score is driven primarily by fragile financial fundamentals, including large ongoing losses, negative equity, and persistent cash burn. Weak technical momentum and an uninformative negative P/E further limit the score, despite early revenue growth.

Positive Factors

Revenue GrowthRevenue has more than doubled from the prior year, indicating improving commercialization traction and growing adoption of the company’s offerings. If this trend persists, a larger revenue base could provide operating leverage and gradually improve the economics of the business.

Negative Factors

Persistent Net LossesThe scale of ongoing losses relative to revenue shows that the current business is far from covering its cost base. Persistent deficits can delay self-funded growth, require additional capital, and make future profitability dependent on substantial revenue expansion or expense reductions.

OncoZenge AB (ONCOZ) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 85.84M
Dividend Yield: ―
Average Volume (3M): 56.28K
Price to Earnings (P/E): -1.6
Beta (1Y): 1.47
Revenue Growth: 115.26%
EPS Growth: -230.43%
Country: Sweden
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

OncoZenge AB Business Overview & Revenue Model

Company Description

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinica...

OncoZenge AB Financial Statement Overview

Summary

Financial performance is constrained to the minimum score because persistent large losses, negative shareholder equity, material liabilities, and sustained negative operating cash flow outweigh the recent revenue growth and strong gross margin.

Income Statement

32Negative

Balance Sheet

18Very Negative

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.84M	2.66M	1,000	3,000	0	0
Gross Profit	3.96M	-4.84M	1,000	3,000	0	0
EBITDA	-25.44M	-15.87M	-8.69M	7.27M	2.77M	-4.89M
Net Income	-26.18M	-15.94M	-8.69M	-15.90M	-46.65M	-3.89M
Balance Sheet
Total Assets	11.73M	15.34M	11.43M	20.34M	36.89M	85.23M
Cash, Cash Equivalents and Short-Term Investments	749.00K	3.71M	3.86M	12.63M	29.14M	51.22M
Total Debt	7.50M	7.50M	0	0	0	0
Total Liabilities	17.03M	15.92M	1.48M	1.70M	2.92M	4.90M
Stockholders Equity	-5.30M	-587.00K	9.95M	18.64M	33.97M	80.32M
Cash Flow
Free Cash Flow	-10.73M	-13.06M	-8.76M	-17.08M	-22.08M	-10.12M
Operating Cash Flow	-23.79M	-13.06M	-8.76M	-17.08M	-22.08M	-4.77M
Investing Cash Flow	0	0	0	570.00K	0	-5.36M
Financing Cash Flow	22.98M	12.91M	0	0	0	51.34M

OncoZenge AB Technical Analysis

Technical Analysis SentimentNegative

Last Price3.10

Price Trends

50DMA3.57Negative

100DMA4.63Negative

200DMA4.82Negative

Market Momentum

MACD-0.14Positive

RSI40.59Neutral

STOCH25.20Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Negative. The current price of 3.10 is below the 20-day moving average (MA) of 3.38, below the 50-day MA of 3.57, and below the 200-day MA of 4.82, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 40.59 is Neutral, neither overbought nor oversold. The STOCH value of 25.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ONCOZ.

OncoZenge AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:ONCOZ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:ONCO	47Neutral	SEK 721.66M	-2.14	―	―	87.23%	35.27%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%
SE:ISOFOL	41Neutral	SEK 383.95M	-5.99	-54.41%	―	―	32.79%
SE:ONCOZ	38Underperform	SEK 85.84M	-1.62	-2775.09%	―	115.26%	-230.43%

* Healthcare Sector Average

Performance Comparison

SE:ONCOZ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:ONCOZ	OncoZenge AB	3.10	-1.27	-29.11%
SE:ONCO	Oncopeptides AB	1.66	-3.81	-69.69%
SE:ISOFOL	Isofol Medical AB	1.27	0.58	84.86%
SE:ELIC	Elicera Therapeutics AB	2.67	-3.27	-55.07%
SE:IMMU	Immunicum AB	5.43	-1.97	-26.62%
SE:CANTA	Cantargia AB	1.72	-1.56	-47.56%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 16, 2026

OncoZenge AB AI Stock Analysis